Sana Cash Flows Other Operating vs Begin Period Cash Flow Analysis
SANA Stock | USD 2.61 0.26 11.06% |
Sana Biotechnology financial indicator trend analysis is much more than just breaking down Sana Biotechnology prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sana Biotechnology is a good investment. Please check the relationship between Sana Biotechnology Cash Flows Other Operating and its Begin Period Cash Flow accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sana Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Sana Stock refer to our How to Trade Sana Stock guide.
Cash Flows Other Operating vs Begin Period Cash Flow
Cash Flows Other Operating vs Begin Period Cash Flow Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sana Biotechnology Cash Flows Other Operating account and Begin Period Cash Flow. At this time, the significance of the direction appears to have pay attention.
The correlation between Sana Biotechnology's Cash Flows Other Operating and Begin Period Cash Flow is -0.86. Overlapping area represents the amount of variation of Cash Flows Other Operating that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Sana Biotechnology, assuming nothing else is changed. The correlation between historical values of Sana Biotechnology's Cash Flows Other Operating and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash Flows Other Operating of Sana Biotechnology are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Cash Flows Other Operating i.e., Sana Biotechnology's Cash Flows Other Operating and Begin Period Cash Flow go up and down completely randomly.
Correlation Coefficient | -0.86 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Cash Flows Other Operating
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most indicators from Sana Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sana Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sana Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Sana Stock refer to our How to Trade Sana Stock guide.As of November 23, 2024, Selling General Administrative is expected to decline to about 46.5 M. In addition to that, Issuance Of Capital Stock is expected to decline to about 30.1 M
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 356.9M | 272.6M | 294.9M | 249.3M | Cost Of Revenue | 17.9M | 27.7M | 30.9M | 16.6M |
Sana Biotechnology fundamental ratios Correlations
Click cells to compare fundamentals
Sana Biotechnology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sana Biotechnology fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 415.7M | 730.3M | 1.1B | 822.7M | 565.3M | 677.9M | |
Other Current Liab | 18.0M | 21.8M | 78.7M | 83.9M | 47.2M | 46.0M | |
Total Current Liabilities | 19.8M | 31.5M | 99.2M | 111.5M | 64.5M | 60.2M | |
Total Stockholder Equity | (142.5M) | (421.2M) | 728.5M | 499.3M | 287.5M | 172.0M | |
Other Liab | 74.7M | 198.9M | 199.9M | 116.0M | 133.4M | 129.7M | |
Net Tangible Assets | (342.4M) | (621.0M) | 528.7M | 299.5M | 344.4M | 361.6M | |
Property Plant And Equipment Net | 69.3M | 109.9M | 161.8M | 159.4M | 145.6M | 118.5M | |
Net Debt | (31.8M) | (340.1M) | (142.1M) | (68.5M) | (29.4M) | (30.9M) | |
Retained Earnings | (144.1M) | (429.4M) | (785.4M) | (1.1B) | (1.3B) | (1.3B) | |
Accounts Payable | 0.0 | 2.3M | 2.2M | 2.9M | 4.1M | 2.1M | |
Cash | 80.0M | 412.0M | 253.0M | 176.8M | 133.5M | 199.1M | |
Non Current Assets Total | 271.4M | 345.8M | 571.3M | 378.3M | 351.8M | 352.1M | |
Non Currrent Assets Other | 2.3M | 2.3M | 13.8M | 9.0M | 6.4M | 6.3M | |
Other Assets | 2.3M | 2.3M | 13.8M | 9.0M | 10.4M | 6.3M | |
Cash And Short Term Investments | 139.0M | 412.0M | 746.9M | 434.0M | 205.2M | 360.7M | |
Short Term Investments | 59.0M | 253.5M | 298.0M | 247.2M | 71.7M | 68.1M | |
Liabilities And Stockholders Equity | 415.7M | 730.3M | 1.1B | 822.7M | 565.3M | 677.9M | |
Non Current Liabilities Total | 538.4M | 1.1B | 301.7M | 211.9M | 213.3M | 324.1M | |
Capital Lease Obligations | 48.2M | 71.9M | 110.9M | 108.3M | 104.1M | 81.3M | |
Other Current Assets | 5.3M | 12.4M | 14.2M | 20.5M | 8.3M | 11.5M | |
Other Stockholder Equity | (415.8M) | 852.9M | 1.5B | 1.6B | 1.6B | 941.7M | |
Total Liab | 558.2M | 1.2B | 400.9M | 323.4M | 277.8M | 367.9M | |
Net Invested Capital | (142.5M) | (421.2M) | 728.5M | 499.3M | 287.5M | 172.0M | |
Property Plant And Equipment Gross | 69.3M | 109.9M | 180.6M | 193.4M | 187.4M | 135.9M | |
Total Current Assets | 144.3M | 384.5M | 558.1M | 444.4M | 213.5M | 325.9M | |
Accumulated Other Comprehensive Income | 26K | 30K | (1.4M) | (4.3M) | (60K) | (63K) | |
Capital Stock | 1K | 2K | 18K | 19K | 20K | 11K | |
Non Current Liabilities Other | 74.7M | 198.9M | 301.7M | 211.9M | 122.4M | 166.8M | |
Net Working Capital | 124.4M | 353.0M | 458.9M | 332.9M | 149.0M | 265.7M | |
Property Plant Equipment | 68.8M | 109.9M | 65.5M | 66.9M | 77.0M | 68.6M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sana Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sana Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sana Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sana Biotechnology Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sana Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Sana Stock refer to our How to Trade Sana Stock guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sana Biotechnology. If investors know Sana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sana Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.40) | Return On Assets (0.31) | Return On Equity (0.93) |
The market value of Sana Biotechnology is measured differently than its book value, which is the value of Sana that is recorded on the company's balance sheet. Investors also form their own opinion of Sana Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Sana Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sana Biotechnology's market value can be influenced by many factors that don't directly affect Sana Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sana Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sana Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sana Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.